# Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients

> **NCT04397653** · PHASE4 · UNKNOWN · sponsor: **Policlinico Casilino ASL RMB** · enrollment: 50 (estimated)

## Conditions studied

- Hypercholesterolemia
- Chronic Kidney Disease Requiring Chronic Dialysis

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Placebo
- **DRUG:** Ezetimibe

## Key facts

- **NCT ID:** NCT04397653
- **Lead sponsor:** Policlinico Casilino ASL RMB
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-04
- **Primary completion:** 2020-11-19
- **Final completion:** 2020-12-14
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397653, "Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04397653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*